Leading DNA vaccine discovery company, Inovio Biomedical Corporation announced that their Scientific Advisory Board Chairman, Dr. David B. Weiner, highlighted advances in the company’s leading electroporation-delivered SynCon™ DNA vaccines at the AIDS Vaccine 2009 Conference in Paris.

The study, led by Dr. Weiner’s team at the University of Pennsylvania, included collaborators from Inovio and Merck. The team previously reported that DNA vaccines delivered using electroporation induced dramatic increases in T-cell and antibody-based immune responses. This collaborative study was the first to directly compare a DNA plasmid-electroporation platform with a recombinant Ad5 vector in an SIV model in non-human primates.

Dr. Weiner presented pre-clinical data showing higher levels of immune responses induced by Inovio’s DNA vaccines than to those induced by the recombinant adenovirus serotype 5 (Ad5) vector. Historically, recombinant Ad5 vector has been shown to be one of the most potent viral vectors for vaccines.

In his presentation, Dr. Weiner also

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Tuesday October 20, 2009

DrStockPick.com Stock Report!

**************************************************************

UnitedHealth Group (NYSE:UNH) reported third quarter results today, including growth in revenues and net earnings and a continued strong financial position. Stephen J. Hemsley, president and chief executive officer of UnitedHealth Group, said, “We combined successful overall cost containment and strong execution in our services businesses to continue to perform during a difficult economic period. This reinforces the value of our diversified business model. We continue to focus on delivering value for customers and stakeholders through responsive, high

...

AngioDynamics, Inc. (ANGO) yesterday reported first quarter fiscal 2010 earnings per share of 9 cents, surpassing the Zacks Consensus Estimate of 8 cents. Earnings per share in the year-ago quarter also reached 9 cents. Sales Net sales in the reported quarter were $50.1 million, increasing 13% year over year. The increase was across all the business segments. On a geographic basis, U.S. sales contributed approximately 90% of total sales and increased roughly 15% year over year. International sales were roughly flat year over year. Peripheral Vascular sales increased 14% year over year to $21.1 million. This was primarily due to the Benephit renal infusion system and Diomed acquisitions. Access sales increased 3% year over year to $16.2 million. Oncology/Surgery sales increased 25% year over year to $12.8 million. Margins Gross margin declined 170 basis points (bps) year over year to 60.2% in the ...

DrStockPick.com Stock Report!

Wednesday August 5, 2009

**************************************************************

Enfora, a provider of intelligent wireless networking solutions, today announced that the Spider(R) AT Asset Tag has been certified by AT&T (NYSE: ATT) for use on its wireless network. Certification is intended to ensure customers an optimal experience when using the Spider AT across the AT&T network.

Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the sale of its Labcaire subsidiary to PuriCore International Limited (”PuriCore”) for a total purchase price of up to $5.6 million. Misonix received $3,600,000 at closing and

...

Angiodynamics, Inc. (ANGO) reported fourth quarter and full fiscal year 2009 results and provided guidance for full fiscal year 2010 yesterday after the close of the market. Excluding extraordinary items, the company reported fourth quarter EPS of $0.14, below the Street’s expectations of $0.15. The company also provided guidance for fiscal 2010 below the Street’s expectations. Quarterly results Net sales in the quarter were $52.8 million, an increase of 13% y/y. Growth in net sales can be attributed to higher sales of vein ablation and oncology products, primarily the company’s embolization product, LCB. Peripheral Vascular sales increased 26% y/y to $22.5 million. Growth was primarily due to the acquisition of laser ablation products from Diomed and the Benephit renal infusion system from FlowMedica. Access sales declined 1% y/y to $17.9 million. The decline was due to the withdrawal of the Centros dialysis catheter from the ...